The Latest Breaking News from EMA

Researchers found cases of the obesity drug putting patients at greater risk of suicidal ideation.

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

NICE says drug is not cost effective and shares fears of side effects

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

As Jasper embarks on promising clinical trials and reports narrower losses, analysts remain bullish, setting ambitious price targets that could indicate substantial returns for investors.

Rowe Racing's appeal against the result of the Nurburgring 24 Hour race has failed, ensuring Scherer Sport Phx drivers Christopher Mies, Dennis Marschall, Frank Stippler and Ricardo Feller remain victorious.

Campaigner welcomes investigation into drug after hundreds of suspected adverse reactions

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

Lietz revealed that he at first "had no idea" about the significance of his pass on team-mate Klaus Bachler into Les Combes, which secured victory for the #91 Manthey EMA Porsche he shared with Yasser Shahin and Morris Schuring, as he had begun the final tour in third place.

A total of 20 drivers are competing in the DTM in 2024, representing nine teams and seven different manufacturers.

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….